Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Robert L. Cuffe"'
Autor:
Robert L. Cuffe, Anna Christina. Grobler, David Dunn, Daniel Meyer, Britt Stancil, David V. Glidden, Brett Hanscom, Deborah Donnell, Amy Cutrell, Ronnie Wang
Publikováno v:
HIV clinical trials, vol 18, iss 5-6
Pre-exposure prophylaxis (PrEP) has demonstrated remarkable effectiveness protecting at-risk individuals from HIV-1 infection. Despite this record of effectiveness, concerns persist about the diminished protective effect observed in women compared wi
Autor:
Mitsuaki Machida, Robert L. Cuffe, Catherine Granier, Carly Barnett, Cunshan Wang, James H. Roger
Publikováno v:
HIV Clinical Trials. 16:170-177
Missing data can compromise inferences from clinical trials, yet the topic has received little attention in the clinical trial community. Shortcomings in commonly used methods used to analyze studies with missing data (complete case, last- or baselin
Autor:
Cynthia Brinson, Anita Rachlis, Joseph J. Eron, Clare A. Brennan, Miguel Górgolas, Keikawus Arastéh, W. Garrett Nichols, Robert L. Cuffe, Steve Almond, Catherine Granier, F Raffi, Keith A. Pappa, Sharon Walmsley
Publikováno v:
AIDS (London, England)
Objectives Dolutegravir (DTG) has been studied in three trials in HIV treatment-naive participants, showing noninferiority compared with raltegravir (RAL), and superiority compared with efavirenz and ritonavir-boosted darunavir. We explored factors t
Publikováno v:
Pharmaceutical Statistics. 11:410-416
Considerable statistical research has been performed in recent years to develop sophisticated statistical methods for handling missing data and dropouts in the analysis of clinical trial data. However, if statisticians and other study team members pr
Publikováno v:
Pharmaceutical Statistics. 10:461-466
Adjusting for covariates makes efficient use of data and can improve the precision of study results or even reduce sample sizes. There is no easy way to adjust for covariates in a non-inferiority study for which the margin is defined as a risk differ
Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial
Publikováno v:
Pharmaceutical Statistics. 8:25-37
In an environment where (i) potential risks to subjects participating in clinical studies need to be managed carefully, (ii) trial costs are increasing, and (iii) there are limited research resources available, it is necessary to prioritize research
Publikováno v:
Pharmaceutical statistics. 13(4)
Background: Inferentially seamless studies are one of the best-known adaptive trial designs. Statistical inference for these studies is a well-studied problem. Regulatory guidance suggests that statistical issues associated with study conduct are not
Publikováno v:
Pharmaceutical statistics. 10(5)
Adjusting for covariates makes efficient use of data and can improve the precision of study results or even reduce sample sizes. There is no easy way to adjust for covariates in a non-inferiority study for which the margin is defined as a risk differ